Intestinal Tissue-Resident Memory T Cells and HIV-1 Persistence During Antiretroviral Therapy
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorANRS, Emerging Infectious Diseases
About this trial
The study aims to better characterize intestinal tissue-resident memory T cells (TRM) in people living with HIV-1 receiving suppressive antiretroviral therapy (ART). TRM cells are key components of tissue immunity and may contribute to HIV-1 persistence within the intestinal mucosa, a major viral reservoir. The phenotypic, transcriptomic, and functional characteristics of intestinal CD4+ and CD8+ TRM cells, their susceptibility to HIV-1 infection, and their potential role as viral reservoirs will be investigated. Blood samples and additional colonic biopsies obtained during routine clinically indicated colonoscopy will be collected from HIV-1-infected participants and HIV-seronegative controls.
Eligibility criteria
Qualifiers
Age ≥ 18 years
Documented HIV-1 infection
Continuous suppressive antiretroviral therapy initiated during chronic infection for at least 12 months
Plasma HIV-1 RNA ≤ 50 copies/mL for at least 6 months under ART (one isolated blip ≤ 200 copies/mL allowed)
Disqualifiers
Group 1: People Living With HIV-1
HIV-2 infection
Inflammatory bowel disease (Crohn's disease or ulcerative colitis) or celiac disease
Platelet count < 50 G/L or uncorrectable coagulation disorders contraindicating biopsies
Trial design
Treatments tested in this trial
- Colonic Mucosal Biopsies
Treatment groups
30 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov